Dermatologic toxicities such as acneiform rash, dry skin, pruritus, erythema, and paronychia have been reported in more than 90% patients receiving anti-EGFR monoclonal antibodies for the treatment of mCRC, although the majority of these toxicities are of mild grade [22]. This evidence concerns the gene EGFR and paronychia.